Relationship between Urinary Liver-Type Fatty Acid-Binding Protein (L-FABP) and Sarcopenia in Spontaneously Diabetic Torii Fatty Rats.
Journal
Journal of diabetes research
ISSN: 2314-6753
Titre abrégé: J Diabetes Res
Pays: England
ID NLM: 101605237
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
09
2019
revised:
16
11
2019
accepted:
26
11
2019
entrez:
15
5
2020
pubmed:
15
5
2020
medline:
19
3
2021
Statut:
epublish
Résumé
Type 2 diabetes (T2D) is a known risk factor for diabetic kidney disease (DKD) and sarcopenia in older patients. Because there may be an interaction between DKD and sarcopenia, the aim of the present study is to investigate the relationship between urinary levels of liver-type fatty acid-binding protein (L-FABP) and sarcopenia using a novel rat model of T2D. Male spontaneously diabetic Torii (SDT) fatty rats ( Increased urinary L-FABP levels, focal glomerular sclerosis, moderate interstitial inflammation and fibrosis, and accumulation of renal oxidative proteins were significantly observed in the SDT fatty rats, compared to the SD rats. Muscle weight, muscle strength, cross-sectional areas of both type I and type IIb muscle fibers, and increasing rate of muscle strength were significantly decreased in the SDT fatty rats compared to the SD rats at 24 weeks. Urinary L-FABP levels at 20 and 24 weeks were significantly negatively correlated with muscle strength. Urinary L-FABP levels at 16 weeks were significantly negatively correlated with the increasing rate of muscle strength. Urinary L-FABP reflects the degree of muscle strength and weight, as well as cross-sectional areas of muscle fibers. Although further clinical study is needed, urinary L-FABP may be useful to monitor the progression of sarcopenia and DKD in T2D patients.
Sections du résumé
BACKGROUND
BACKGROUND
Type 2 diabetes (T2D) is a known risk factor for diabetic kidney disease (DKD) and sarcopenia in older patients. Because there may be an interaction between DKD and sarcopenia, the aim of the present study is to investigate the relationship between urinary levels of liver-type fatty acid-binding protein (L-FABP) and sarcopenia using a novel rat model of T2D.
METHODS
METHODS
Male spontaneously diabetic Torii (SDT) fatty rats (
RESULTS
RESULTS
Increased urinary L-FABP levels, focal glomerular sclerosis, moderate interstitial inflammation and fibrosis, and accumulation of renal oxidative proteins were significantly observed in the SDT fatty rats, compared to the SD rats. Muscle weight, muscle strength, cross-sectional areas of both type I and type IIb muscle fibers, and increasing rate of muscle strength were significantly decreased in the SDT fatty rats compared to the SD rats at 24 weeks. Urinary L-FABP levels at 20 and 24 weeks were significantly negatively correlated with muscle strength. Urinary L-FABP levels at 16 weeks were significantly negatively correlated with the increasing rate of muscle strength.
CONCLUSIONS
CONCLUSIONS
Urinary L-FABP reflects the degree of muscle strength and weight, as well as cross-sectional areas of muscle fibers. Although further clinical study is needed, urinary L-FABP may be useful to monitor the progression of sarcopenia and DKD in T2D patients.
Identifiants
pubmed: 32405506
doi: 10.1155/2020/7614035
pmc: PMC7201485
doi:
Substances chimiques
Biomarkers
0
Fabp1 protein, rat
0
Fatty Acid-Binding Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7614035Informations de copyright
Copyright © 2020 Jun Tanabe et al.
Déclaration de conflit d'intérêts
T.S. is the director and a senior scientist at CMIC Holdings Co., Ltd., and K.O. is a scientist at CMIC Holdings Co., Ltd., which produced the kits for L-FABP analysis. All other authors declare no conflicts of interest.
Références
Biofactors. 2009 Jan-Feb;35(1):28-35
pubmed: 19319843
Am J Pathol. 2009 Jun;174(6):2096-106
pubmed: 19435794
Hypertension. 2012 Oct;60(4):973-80
pubmed: 22926951
J Toxicol Pathol. 2018 Apr;31(2):113-123
pubmed: 29750000
Eur J Pharmacol. 2017 Nov 15;815:88-97
pubmed: 28888756
J Biol Chem. 2002 Jul 5;277(27):23977-80
pubmed: 11997383
Skelet Muscle. 2011 Jan 24;1(1):4
pubmed: 21798082
Kidney Blood Press Res. 2018;43(6):1716-1729
pubmed: 30472704
Diabetologia. 2015 Aug;58(8):1693-8
pubmed: 26003326
Hypertens Res. 2019 Oct;42(10):1518-1527
pubmed: 31168059
Nat Med. 2017 Apr;23(4):508-516
pubmed: 28263310
Diabetes Res Clin Pract. 2016 Aug;118:121-9
pubmed: 27368064
J Am Soc Nephrol. 2007 Nov;18(11):2894-902
pubmed: 17942962
Endocrinology. 2015 Oct;156(10):3638-48
pubmed: 26241123
Free Radic Biol Med. 2003 Jul 1;35(1):9-16
pubmed: 12826251
Exp Gerontol. 2017 May;91:72-78
pubmed: 28257932
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8665-70
pubmed: 19433800
Scand J Med Sci Sports. 2018 Jan;28(1):152-160
pubmed: 28247579
Clin Exp Nephrol. 2016 Apr;20(2):195-203
pubmed: 26189083
J Am Soc Nephrol. 2016 Sep;27(9):2861-71
pubmed: 26823551
Am J Physiol. 1995 Mar;268(3 Pt 1):E453-7
pubmed: 7900793
Exp Anim. 2008 Apr;57(2):111-21
pubmed: 18421173
Am J Physiol Heart Circ Physiol. 2001 Jul;281(1):H241-52
pubmed: 11406491
Kidney Int. 2014 Jun;85(6):1330-9
pubmed: 24284514
PLoS One. 2012;7(10):e46668
pubmed: 23071610
Exp Anim. 2005 Jan;54(1):13-20
pubmed: 15725677
Lancet Diabetes Endocrinol. 2014 Oct;2(10):819-29
pubmed: 24731660
FEBS Lett. 1993 Jul 12;326(1-3):189-91
pubmed: 8325368
PLoS One. 2014 Nov 17;9(11):e111949
pubmed: 25401694
Am J Physiol Endocrinol Metab. 2015 Oct 1;309(7):E651-62
pubmed: 26244519
Clin Exp Nephrol. 2017 Oct;21(5):810-817
pubmed: 28197733
PLoS One. 2015 Sep 17;10(9):e0138037
pubmed: 26379244
J Am Soc Nephrol. 2014 Dec;25(12):2800-11
pubmed: 25012168
Nat Rev Nephrol. 2017 Mar;13(3):152-168
pubmed: 28138130
Ann Clin Lab Sci. 2000 Oct;30(4):346-53
pubmed: 11045758